TNXP: Tonix Pharmaceuticals Holding Corp. Narxning prognoz qilingan daromadga nisbati
Tonix Pharmaceuticals (TNXP) vaksinalar va og'riqni boshqarish vositalarini ishlab chiqish uchun ilmiy markazlar bilan ittifoqlarga tayanadi. Kutilayotgan narx-sotuvlar nisbati ushbu kutishlarni vizuallashtiradi, bunda ushbu ko'rsatkich hozirda 1.30 darajasida turibdi. Kompaniya hozirda o'z patentlaridan ortiqcha foyda olish umidida mablag'larni tadqiqot va ishlanmalarga (R&D) yo'naltirmoqda. Sektordagi ko'plab raqobatchilardan ustun bo'lish uchun firma o'zining ishlanmalar portfelini jadal tezlashtirmoqda.
Tonix Pharmaceuticals Holding Corp. - tahliliy kesimlar va asosiy koʻrsatkichlar (TNXP)
- aksiya narxi va konsensus maqsadli narx:
- bozor kapitallashuvi haqida ma'lumot:
- xususiy kapitalning balans qiymati ko'rsatkichlari:
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning xususiy kapitalga nisbati Tonix Pharmaceuticals|TNXP - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Qisqa muddatli qarzning o'z kapitaliga nisbati Tonix Pharmaceuticals Holding Corp.|TNXP - Jamlangan qarz majburiyatlari|Qarzning balans kapitallashuviga nisbati Tonix Pharmaceuticals|TNXP - Uzoq muddatli majburiyatlar|Kompaniyaning qisqa muddatli qarzlari Tonix Pharmaceuticals|Tezkor likvidlik koeffitsiyenti tonixpharma.com
- biznes foydasi va investitsiya koeffitsiyentlari ma'lumotlari:
TNXP - Sof foyda|Kutilayotgan foyda Tonix Pharmaceuticals|TNXP - Kompaniya qiymatining sof foydaga nisbati|Kelajakdagi narxning foydaga nisbati tonixpharma.com|TNXP - Narx-foyda va o‘sish multiplikatori|EV/EBITDA multiplikatori Tonix Pharmaceuticals|TNXP - EBITDA operatsion foydasi|Bir aksiya uchun sof foyda (EPS TTM) Tonix Pharmaceuticals|TNXP - So'nggi 12 oy davomida bir aksiya uchun sof foyda|Choraklik EPS foyda o'sishi tonixpharma.com|TNXP - Joriy yilda bir aksiya uchun foydaning o'sish sur'ati|Keyingi yil uchun bir aksiya uchun kutilayotgan foyda o'sishi Tonix Pharmaceuticals
- sotuvlar va tushum ko'rsatkichlari:
Kompaniyaning jamlanma tahlili:TNXP (Tonix Pharmaceuticals Holding Corp.)
Forward P/S ko'rsatkichi joriy bozor kapitalizatsiyasini tahlilchilar prognozlariga asoslangan kutilayotgan daromadlar bilan solishtiradi va kelajakdagi pul oqimlari uchun to'langan premium miqdorini aniqlaydi. Forward P/S baholashining tarixini tahlil qilish orqali investor Tonix Pharmaceuticals (TNXP) kompaniyasining haddan tashqari yuqori baholanishi xatarlarini aniqlashi mumkin, chunki ushbu kompaniyaning moliyaviy barqarorligi dori vositalarini ishlab chiqish bosqichida barqaror daromadlar yo'qligi sababli tashqi moliyalashtirishga kritik darajada bog'liqdir.
Toʻgʻridan-toʻgʻri raqobatchilar
Forvard P/S multiplikatori HLN (Haleon PLC)|Forvard P/S multiplikatori Kenvue Corp KVUE|Verona Pharma PLC - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati jyongbio.com|LGND: Forvard P/S multiplikatori|Kapitalizatsiyaning prognoz qilingan daromadga nisbati AMRX|Narxning prognoz qilingan daromadga nisbati Perrigo Company|Bozor kapitallashuvining kelajakdagi daromadga nisbati Alvotech ALVO|Forvard P/S multiplikatori LQDA|GLPG: Kelajakdagi narxning daromadga nisbati|Forvard P/S multiplikatori ANIP (ANI Pharmaceuticals, Inc.)|Kapitalizatsiyaning kutilayotgan sotuvga nisbati MannKind Corp (MNKD)|AMPH: Forvard narx/daromad multiplikatori|Sotuvga nisbatan forvard narx PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Narxning prognoz qilingan daromadga nisbati|Kapitalizatsiyaning prognoz qilingan daromadga nisbati TBPH|AQST (Aquestive Corp) - Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori scPharmaceuticals Inc. (SCPH)|Forvard narx/daromad multiplikatori TECX (Tectonic Therapeutic, Inc.)|SXTC (SXT Pharmaceuticals) - Sotuvga nisbatan forvard narx|Forvard P/S multiplikatori EPRX (Eupraxia Pharmaceuticals)|Sotuvga nisbatan forvard narx BHST|Invizyne Technologies - Forvard P/S multiplikatori|oramed.com (ORMP) - Forvard narx/daromad multiplikatori|ENTX (enterabio.com) - Forvard narx/daromad multiplikatori|Kapitalizatsiyaning prognoz qilingan daromadga nisbati HYFT|ABVC (ABVC BioPharma, Inc) - Forvard P/S multiplikatori|Forvard P/S multiplikatori cumberlandpharma.com|Narxning prognoz qilingan daromadga nisbati Quantum BioPharma (QNTM)|FibroGen (FGEN) - Prognoz narxning daromadga nisbati|Forvard P/S multiplikatori TELO (telomirpharma.com)|RANI - Forvard narx/daromad multiplikatori|SNYR - Narxning prognoz qilingan daromadga nisbati|rallybio.com - Narxning kutilayotgan daromadga nisbati|LEXX: Forvard P/S multiplikatori|Forvard narx/daromad multiplikatori Pulmatrix Inc|PTHL (Pheton Holdings) - Forvard P/S multiplikatori|Bozor kapitallashuvining kelajakdagi daromadga nisbati Aptorum Group Limited APM|Narxning prognoz qilingan daromadga nisbati Lyra Therapeutics (LYRA)|Forvard narx/daromad multiplikatori Impact BioMedical Inc IBO|Narxning prognoz qilingan daromadga nisbati tnfpharma.com TNFA|Sotuvga nisbatan forvard narx YCBD|PainReform Ltd - Forvard P/S multiplikatori|Altamira Therapeutics Ltd (CYTO) - Forvard narx/daromad multiplikatori|lipella.com (LIPO) - Narxning prognoz qilingan daromadga nisbati|OptiNose (OPTN) - Forvard P/S multiplikatori|PIRS (Pieris Pharmaceuticals Inc) - Forvard P/S multiplikatori|PROC: Sotuvga nisbatan forvard narx|Narxning prognoz qilingan daromadga nisbati Petros Pharmaceuticals, Inc. (PTPI)|Forvard P/S multiplikatori Qilian International Corp (QLI)|ACELYRIN, Inc. - Forvard narx/daromad multiplikatori|Forvard P/S multiplikatori tffpharma.com TFFP
